Fig. 3: Outcomes by subgroups of concurrent and transformed DLBCL. | Blood Cancer Journal

Fig. 3: Outcomes by subgroups of concurrent and transformed DLBCL.

From: Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study

Fig. 3

a Progression-free survival (PFS) in the subgroups of concurrent and transformed DLBCL. b Event-free survival (EFS) in the subgroups of concurrent and transformed DLBCL. c Overall survival (OS) in the subgroups of concurrent and transformed DLBCL. KM est Kaplan–Meier estimates, NE not estimable, HR hazard ratio.

Back to article page